We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 26, 2021

HER2-Low Status and Response to Neoadjuvant Chemotherapy in HER2-Negative Early Breast Cancer

Breast Cancer Research and Treatment

 

Additional Info

Breast Cancer Research and Treatment
HER2-Low Status and Response to Neoadjuvant Chemotherapy in HER2 Negative Early Breast Cancer
Breast Cancer Res Treat 2021 Aug 18;[EPub Ahead of Print], L de Moura Leite, MG Cesca, MC Tavares, DM Santana, EF Saldanha, PT Guimarães, DDS Sá, MFE Simões, RL Viana, FG Rocha, SK Loose, SF Silva, R Pirolli, CAZ Fogassa, BRS Mattos, FAB Campos, SM Sanches, VCC de Lima, NF Pondé

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading